JPWO2019145729A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019145729A5 JPWO2019145729A5 JP2020561950A JP2020561950A JPWO2019145729A5 JP WO2019145729 A5 JPWO2019145729 A5 JP WO2019145729A5 JP 2020561950 A JP2020561950 A JP 2020561950A JP 2020561950 A JP2020561950 A JP 2020561950A JP WO2019145729 A5 JPWO2019145729 A5 JP WO2019145729A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- cancer
- arthritis
- syndrome
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 201000010099 disease Diseases 0.000 claims 33
- 206010003246 Arthritis Diseases 0.000 claims 32
- 125000000217 alkyl group Chemical group 0.000 claims 29
- 150000001875 compounds Chemical class 0.000 claims 25
- 150000003839 salts Chemical class 0.000 claims 22
- 239000011780 sodium chloride Substances 0.000 claims 22
- 201000010874 syndrome Diseases 0.000 claims 21
- -1 piperidil Chemical group 0.000 claims 18
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 229910052799 carbon Inorganic materials 0.000 claims 9
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 8
- 201000011510 cancer Diseases 0.000 claims 8
- 201000007270 liver cancer Diseases 0.000 claims 8
- 201000008482 osteoarthritis Diseases 0.000 claims 8
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 6
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 125000004093 cyano group Chemical group *C#N 0.000 claims 5
- 125000005843 halogen group Chemical group 0.000 claims 5
- 230000002757 inflammatory Effects 0.000 claims 5
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 4
- 206010009944 Colon cancer Diseases 0.000 claims 4
- 206010014733 Endometrial cancer Diseases 0.000 claims 4
- 206010020772 Hypertension Diseases 0.000 claims 4
- 206010061218 Inflammation Diseases 0.000 claims 4
- 208000006897 Interstitial Lung Disease Diseases 0.000 claims 4
- 208000008338 Non-alcoholic Fatty Liver Disease Diseases 0.000 claims 4
- 108009000135 Nonalcoholic fatty liver disease Proteins 0.000 claims 4
- 208000001132 Osteoporosis Diseases 0.000 claims 4
- 206010037162 Psoriatic arthropathy Diseases 0.000 claims 4
- 102100000534 ROCK1 Human genes 0.000 claims 4
- 101700034252 ROCK1 Proteins 0.000 claims 4
- 102100000533 ROCK2 Human genes 0.000 claims 4
- 101700011174 ROCK2 Proteins 0.000 claims 4
- 206010072736 Rheumatic disease Diseases 0.000 claims 4
- 206010039073 Rheumatoid arthritis Diseases 0.000 claims 4
- 206010041823 Squamous cell carcinoma Diseases 0.000 claims 4
- 206010042953 Systemic sclerosis Diseases 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 4
- 125000000623 heterocyclic group Chemical group 0.000 claims 4
- 201000009794 idiopathic pulmonary fibrosis Diseases 0.000 claims 4
- 230000004054 inflammatory process Effects 0.000 claims 4
- 230000002093 peripheral Effects 0.000 claims 4
- 201000001263 psoriatic arthritis Diseases 0.000 claims 4
- 230000000306 recurrent Effects 0.000 claims 4
- 201000009594 systemic scleroderma Diseases 0.000 claims 4
- 241001553178 Arachis glabrata Species 0.000 claims 3
- 206010003210 Arteriosclerosis Diseases 0.000 claims 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 3
- 210000004392 Genitalia Anatomy 0.000 claims 3
- 206010025135 Lupus erythematosus Diseases 0.000 claims 3
- 210000003205 Muscles Anatomy 0.000 claims 3
- 208000003926 Myelitis Diseases 0.000 claims 3
- 206010038932 Retinopathy Diseases 0.000 claims 3
- 206010038923 Retinopathy Diseases 0.000 claims 3
- 201000001320 atherosclerosis Diseases 0.000 claims 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims 3
- 201000003146 cystitis Diseases 0.000 claims 3
- 201000004624 dermatitis Diseases 0.000 claims 3
- 231100000406 dermatitis Toxicity 0.000 claims 3
- 125000001072 heteroaryl group Chemical group 0.000 claims 3
- 201000006417 multiple sclerosis Diseases 0.000 claims 3
- 201000009859 osteochondrosis Diseases 0.000 claims 3
- 201000004681 psoriasis Diseases 0.000 claims 3
- 230000000552 rheumatic Effects 0.000 claims 3
- 230000036262 stenosis Effects 0.000 claims 3
- 200000000009 stenosis Diseases 0.000 claims 3
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 2
- BTANRVKWQNVYAZ-UHFFFAOYSA-N 2-Butanol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 claims 2
- BUDQDWGNQVEFAC-UHFFFAOYSA-N 3,4-dihydro-2H-pyran Chemical group C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 claims 2
- 125000004008 6 membered carbocyclic group Chemical group 0.000 claims 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 2
- 208000009956 Adenocarcinoma Diseases 0.000 claims 2
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims 2
- 206010001897 Alzheimer's disease Diseases 0.000 claims 2
- 206010002383 Angina pectoris Diseases 0.000 claims 2
- 206010062599 Arterial occlusive disease Diseases 0.000 claims 2
- 206010003225 Arteriospasm coronary Diseases 0.000 claims 2
- 206010003267 Arthritis reactive Diseases 0.000 claims 2
- 208000006673 Asthma Diseases 0.000 claims 2
- 210000000941 Bile Anatomy 0.000 claims 2
- 206010004593 Bile duct cancer Diseases 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 206010007554 Cardiac failure Diseases 0.000 claims 2
- 206010059109 Cerebral vasoconstriction Diseases 0.000 claims 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 2
- 208000002849 Chondrocalcinosis Diseases 0.000 claims 2
- 206010012601 Diabetes mellitus Diseases 0.000 claims 2
- 208000007342 Diabetic Nephropathy Diseases 0.000 claims 2
- 206010061835 Diabetic nephropathy Diseases 0.000 claims 2
- 208000010228 Erectile Dysfunction Diseases 0.000 claims 2
- 206010016654 Fibrosis Diseases 0.000 claims 2
- 206010017758 Gastric cancer Diseases 0.000 claims 2
- 208000010412 Glaucoma Diseases 0.000 claims 2
- 208000005017 Glioblastoma Diseases 0.000 claims 2
- 206010019280 Heart failure Diseases 0.000 claims 2
- 208000006454 Hepatitis Diseases 0.000 claims 2
- 206010073071 Hepatocellular carcinoma Diseases 0.000 claims 2
- 201000001971 Huntington's disease Diseases 0.000 claims 2
- 206010021972 Inflammatory bowel disease Diseases 0.000 claims 2
- 206010061255 Ischaemia Diseases 0.000 claims 2
- 208000009883 Joint Disease Diseases 0.000 claims 2
- 210000004185 Liver Anatomy 0.000 claims 2
- 210000004072 Lung Anatomy 0.000 claims 2
- 206010025654 Malignant melanoma of sites other than skin Diseases 0.000 claims 2
- 208000003250 Mixed Connective Tissue Disease Diseases 0.000 claims 2
- 210000000944 Nerve Tissue Anatomy 0.000 claims 2
- 208000002154 Non-Small-Cell Lung Carcinoma Diseases 0.000 claims 2
- 108009000071 Non-small cell lung cancer Proteins 0.000 claims 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 2
- 206010031264 Osteonecrosis Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims 2
- 206010061536 Parkinson's disease Diseases 0.000 claims 2
- 208000005987 Polymyositis Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000005069 Pulmonary Fibrosis Diseases 0.000 claims 2
- 208000002815 Pulmonary Hypertension Diseases 0.000 claims 2
- 208000002574 Reactive Arthritis Diseases 0.000 claims 2
- 206010038389 Renal cancer Diseases 0.000 claims 2
- 206010039491 Sarcoma Diseases 0.000 claims 2
- 210000003491 Skin Anatomy 0.000 claims 2
- 208000000587 Small Cell Lung Carcinoma Diseases 0.000 claims 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims 2
- 208000006011 Stroke Diseases 0.000 claims 2
- 210000001550 Testis Anatomy 0.000 claims 2
- UWYZHKAOTLEWKK-UHFFFAOYSA-N Tetrahydroisoquinoline Chemical group C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 claims 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 2
- 208000001072 Type 2 Diabetes Mellitus Diseases 0.000 claims 2
- 206010046766 Uterine cancer Diseases 0.000 claims 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 2
- 230000001476 alcoholic Effects 0.000 claims 2
- 201000008937 atopic dermatitis Diseases 0.000 claims 2
- 230000001363 autoimmune Effects 0.000 claims 2
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims 2
- 125000002837 carbocyclic group Chemical group 0.000 claims 2
- 125000004432 carbon atoms Chemical group C* 0.000 claims 2
- 210000004027 cells Anatomy 0.000 claims 2
- 201000007455 central nervous system cancer Diseases 0.000 claims 2
- 201000008779 central nervous system disease Diseases 0.000 claims 2
- 201000010881 cervical cancer Diseases 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 230000001684 chronic Effects 0.000 claims 2
- 201000000159 corneal neovascularization Diseases 0.000 claims 2
- 201000003278 cryoglobulinemia Diseases 0.000 claims 2
- 238000002425 crystallisation Methods 0.000 claims 2
- 230000005712 crystallization Effects 0.000 claims 2
- 201000011275 epicondylitis Diseases 0.000 claims 2
- 201000004101 esophageal cancer Diseases 0.000 claims 2
- 230000004761 fibrosis Effects 0.000 claims 2
- 230000002496 gastric Effects 0.000 claims 2
- 201000005569 gout Diseases 0.000 claims 2
- 201000010536 head and neck cancer Diseases 0.000 claims 2
- 231100000283 hepatitis Toxicity 0.000 claims 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 2
- 230000001969 hypertrophic Effects 0.000 claims 2
- 125000002883 imidazolyl group Chemical group 0.000 claims 2
- 201000001881 impotence Diseases 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- 230000000366 juvenile Effects 0.000 claims 2
- 201000010982 kidney cancer Diseases 0.000 claims 2
- 201000005249 lung adenocarcinoma Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- 125000002757 morpholinyl group Chemical group 0.000 claims 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N n-butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 239000008177 pharmaceutical agent Substances 0.000 claims 2
- 201000007552 pituitary carcinoma Diseases 0.000 claims 2
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical group OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 201000001947 reflex sympathetic dystrophy Diseases 0.000 claims 2
- 230000001105 regulatory Effects 0.000 claims 2
- 201000002793 renal fibrosis Diseases 0.000 claims 2
- 200000000008 restenosis Diseases 0.000 claims 2
- 201000000306 sarcoidosis Diseases 0.000 claims 2
- 201000002661 spondylitis Diseases 0.000 claims 2
- 210000004500 stellate cell Anatomy 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 201000004595 synovitis Diseases 0.000 claims 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N t-BuOH Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 claims 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Chemical group C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims 2
- 201000002510 thyroid cancer Diseases 0.000 claims 2
- 210000001519 tissues Anatomy 0.000 claims 2
- 230000001256 tonic Effects 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- URSPTJYSBTXILH-UHFFFAOYSA-N 1-methylidenepiperazin-1-ium-4-ide Chemical group C=[N+]1CC[N-]CC1 URSPTJYSBTXILH-UHFFFAOYSA-N 0.000 claims 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical group C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 claims 1
- GCNTZFIIOFTKIY-UHFFFAOYSA-N 1H-pyridin-4-one Chemical group OC1=CC=NC=C1 GCNTZFIIOFTKIY-UHFFFAOYSA-N 0.000 claims 1
- MSTDXOZUKAQDRL-UHFFFAOYSA-N 2,3-dihydrochromen-4-one Chemical group C1=CC=C2C(=O)CCOC2=C1 MSTDXOZUKAQDRL-UHFFFAOYSA-N 0.000 claims 1
- VSWICNJIUPRZIK-UHFFFAOYSA-N 2-piperideine Chemical group C1CNC=CC1 VSWICNJIUPRZIK-UHFFFAOYSA-N 0.000 claims 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 claims 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N 289-95-2 Chemical group C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims 1
- YRLORWPBJZEGBX-UHFFFAOYSA-N 3,4-dihydro-2H-1,4-benzoxazine Chemical class C1=CC=C2NCCOC2=C1 YRLORWPBJZEGBX-UHFFFAOYSA-N 0.000 claims 1
- 125000001054 5 membered carbocyclic group Chemical group 0.000 claims 1
- 206010000748 Acute febrile neutrophilic dermatosis Diseases 0.000 claims 1
- 201000004304 Addison's disease Diseases 0.000 claims 1
- 208000002496 Adult-Onset Still's Disease Diseases 0.000 claims 1
- 210000003423 Ankle Anatomy 0.000 claims 1
- MYYIAHXIVFADCU-QMMMGPOBSA-N Anserine Chemical compound CN1C=NC=C1C[C@H](NC(=O)CC[NH3+])C([O-])=O MYYIAHXIVFADCU-QMMMGPOBSA-N 0.000 claims 1
- 108010085443 Anserine Proteins 0.000 claims 1
- 208000008637 Anti-Glomerular Basement Membrane Disease Diseases 0.000 claims 1
- 206010002961 Aplasia Diseases 0.000 claims 1
- 206010053555 Arthritis bacterial Diseases 0.000 claims 1
- 206010003256 Arthritis gonococcal Diseases 0.000 claims 1
- 206010060968 Arthritis infective Diseases 0.000 claims 1
- 206010003274 Arthritis viral Diseases 0.000 claims 1
- 206010003284 Arthropathy Diseases 0.000 claims 1
- 206010003816 Autoimmune disease Diseases 0.000 claims 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims 1
- BNBQRQQYDMDJAH-UHFFFAOYSA-N Benzodioxan Chemical class C1=CC=C2OCCOC2=C1 BNBQRQQYDMDJAH-UHFFFAOYSA-N 0.000 claims 1
- 206010004661 Biliary cirrhosis primary Diseases 0.000 claims 1
- 210000001185 Bone Marrow Anatomy 0.000 claims 1
- 210000000988 Bone and Bones Anatomy 0.000 claims 1
- 206010056377 Bone tuberculosis Diseases 0.000 claims 1
- 241000589562 Brucella Species 0.000 claims 1
- 206010006811 Bursitis Diseases 0.000 claims 1
- 125000006414 CCl Chemical group ClC* 0.000 claims 1
- 201000002829 CREST syndrome Diseases 0.000 claims 1
- 229940043256 Calcium Pyrophosphate Drugs 0.000 claims 1
- JUNWLZAGQLJVLR-UHFFFAOYSA-J Calcium pyrophosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])(=O)OP([O-])([O-])=O JUNWLZAGQLJVLR-UHFFFAOYSA-J 0.000 claims 1
- 240000000218 Cannabis sativa Species 0.000 claims 1
- 210000000845 Cartilage Anatomy 0.000 claims 1
- 206010008334 Cervicobrachial syndrome Diseases 0.000 claims 1
- 206010008609 Cholangitis sclerosing Diseases 0.000 claims 1
- 206010008690 Chondrocalcinosis pyrophosphate Diseases 0.000 claims 1
- 206010060774 Chondrosis Diseases 0.000 claims 1
- VZWXIQHBIQLMPN-UHFFFAOYSA-N Chromane Chemical group C1=CC=C2CCCOC2=C1 VZWXIQHBIQLMPN-UHFFFAOYSA-N 0.000 claims 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 claims 1
- 208000010007 Cogan Syndrome Diseases 0.000 claims 1
- 206010057668 Cognitive disease Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 206010010121 Compartment syndrome Diseases 0.000 claims 1
- 208000001590 Congenital Abnormality Diseases 0.000 claims 1
- 208000010247 Contact Dermatitis Diseases 0.000 claims 1
- HPXRVTGHNJAIIH-UHFFFAOYSA-N Cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 claims 1
- XCIXKGXIYUWCLL-UHFFFAOYSA-N Cyclopentanol Chemical compound OC1CCCC1 XCIXKGXIYUWCLL-UHFFFAOYSA-N 0.000 claims 1
- LPIQUOYDBNQMRZ-UHFFFAOYSA-N Cyclopentene Chemical group C1CC=CC1 LPIQUOYDBNQMRZ-UHFFFAOYSA-N 0.000 claims 1
- YOXHCYXIAVIFCZ-UHFFFAOYSA-N Cyclopropanol Chemical compound OC1CC1 YOXHCYXIAVIFCZ-UHFFFAOYSA-N 0.000 claims 1
- 206010011732 Cyst Diseases 0.000 claims 1
- 206010011831 Cytomegalovirus infection Diseases 0.000 claims 1
- 208000006313 Delayed Hypersensitivity Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 206010012442 Dermatitis contact Diseases 0.000 claims 1
- 206010073767 Developmental hip dysplasia Diseases 0.000 claims 1
- 206010013801 Duchenne muscular dystrophy Diseases 0.000 claims 1
- 208000004232 Enteritis Diseases 0.000 claims 1
- 208000007985 Erythema Infectiosum Diseases 0.000 claims 1
- 229950010333 Exalamide Drugs 0.000 claims 1
- 206010069837 Eye complication associated with device Diseases 0.000 claims 1
- 201000005603 Fabry disease Diseases 0.000 claims 1
- 206010016207 Familial mediterranean fever Diseases 0.000 claims 1
- 208000001948 Farber Lipogranulomatosis Diseases 0.000 claims 1
- 206010016629 Fibroma Diseases 0.000 claims 1
- 208000001640 Fibromyalgia Diseases 0.000 claims 1
- 208000004067 Flatfoot Diseases 0.000 claims 1
- 241000233866 Fungi Species 0.000 claims 1
- 206010018620 Goodpasture's syndrome Diseases 0.000 claims 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims 1
- 208000003807 Graves Disease Diseases 0.000 claims 1
- 201000004779 Graves' disease Diseases 0.000 claims 1
- 206010018872 Haemochromatosis Diseases 0.000 claims 1
- 208000002672 Hepatitis B Diseases 0.000 claims 1
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 claims 1
- 206010020118 Histiocytosis Diseases 0.000 claims 1
- 206010020880 Hypertrophy Diseases 0.000 claims 1
- 208000002370 Immune Complex Disease Diseases 0.000 claims 1
- WRSXUNSJGJUKHE-UHFFFAOYSA-N Indazole Chemical group C1=CC=C[C]2C=NN=C21 WRSXUNSJGJUKHE-UHFFFAOYSA-N 0.000 claims 1
- 102000004877 Insulin Human genes 0.000 claims 1
- 108090001061 Insulin Proteins 0.000 claims 1
- GWVMLCQWXVFZCN-UHFFFAOYSA-N Isoindoline Chemical group C1=CC=C2CNCC2=C1 GWVMLCQWXVFZCN-UHFFFAOYSA-N 0.000 claims 1
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 1
- 201000007313 Kawasaki disease Diseases 0.000 claims 1
- 201000005417 Legg-Calve-Perthes disease Diseases 0.000 claims 1
- 206010024377 Leukocytoclastic vasculitis Diseases 0.000 claims 1
- 206010061289 Metastatic neoplasm Diseases 0.000 claims 1
- 208000001725 Mucocutaneous Lymph Node Syndrome Diseases 0.000 claims 1
- 208000002678 Mucopolysaccharidosis Diseases 0.000 claims 1
- 206010028093 Mucopolysaccharidosis Diseases 0.000 claims 1
- 206010028372 Muscular weakness Diseases 0.000 claims 1
- 241000204031 Mycoplasma Species 0.000 claims 1
- 206010067103 Ocular surface disease Diseases 0.000 claims 1
- 210000002221 Olecranon Process Anatomy 0.000 claims 1
- 201000005277 Osgood-Schlatter's disease Diseases 0.000 claims 1
- 208000010191 Osteitis Deformans Diseases 0.000 claims 1
- 208000002804 Osteochondritis Diseases 0.000 claims 1
- 208000000035 Osteochondroma Diseases 0.000 claims 1
- 206010031240 Osteodystrophy Diseases 0.000 claims 1
- 206010068786 Overlap syndrome Diseases 0.000 claims 1
- 206010033647 Pancreatitis acute Diseases 0.000 claims 1
- 201000002872 Plica syndrome Diseases 0.000 claims 1
- 206010036030 Polyarthritis Diseases 0.000 claims 1
- 206010065159 Polychondritis Diseases 0.000 claims 1
- 240000001203 Potentilla anserina Species 0.000 claims 1
- 206010037549 Purpura Diseases 0.000 claims 1
- 241001672981 Purpura Species 0.000 claims 1
- 240000001987 Pyrus communis Species 0.000 claims 1
- 235000014443 Pyrus communis Nutrition 0.000 claims 1
- 206010037912 Raynaud's phenomenon Diseases 0.000 claims 1
- 206010038294 Reiter's syndrome Diseases 0.000 claims 1
- 206010039227 Rotator cuff syndrome Diseases 0.000 claims 1
- 241000607142 Salmonella Species 0.000 claims 1
- 206010039447 Salmonellosis Diseases 0.000 claims 1
- 208000010157 Sclerosing Cholangitis Diseases 0.000 claims 1
- 206010040070 Septic shock Diseases 0.000 claims 1
- 206010040400 Serum sickness Diseases 0.000 claims 1
- 241000607768 Shigella Species 0.000 claims 1
- 206010040550 Shigella infection Diseases 0.000 claims 1
- 208000003001 Spinal Tuberculosis Diseases 0.000 claims 1
- 210000000952 Spleen Anatomy 0.000 claims 1
- 206010063402 Stickler's syndrome Diseases 0.000 claims 1
- 241000272534 Struthio camelus Species 0.000 claims 1
- 208000010265 Sweet Syndrome Diseases 0.000 claims 1
- 208000002240 Tennis Elbow Diseases 0.000 claims 1
- YBRBMKDOPFTVDT-UHFFFAOYSA-N Tert-Butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 claims 1
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N Tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 claims 1
- 235000015450 Tilia cordata Nutrition 0.000 claims 1
- 235000011941 Tilia x europaea Nutrition 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 206010048873 Traumatic arthritis Diseases 0.000 claims 1
- 206010064996 Ulcerative keratitis Diseases 0.000 claims 1
- 206010047116 Vascular inflammations Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 208000004762 Vasculitis, Leukocytoclastic, Cutaneous Diseases 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 206010047931 Whipple's disease Diseases 0.000 claims 1
- 201000001203 Wilson disease Diseases 0.000 claims 1
- 201000003229 acute pancreatitis Diseases 0.000 claims 1
- 239000000853 adhesive Substances 0.000 claims 1
- 230000001070 adhesive Effects 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 230000000172 allergic Effects 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 230000002491 angiogenic Effects 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000038129 antigens Human genes 0.000 claims 1
- 108091007172 antigens Proteins 0.000 claims 1
- 229940111121 antirheumatic drugs Quinolines Drugs 0.000 claims 1
- 201000008804 arthropathy Diseases 0.000 claims 1
- 125000004429 atoms Chemical group 0.000 claims 1
- 125000005334 azaindolyl group Chemical group N1N=C(C2=CC=CC=C12)* 0.000 claims 1
- 125000002393 azetidinyl group Chemical group 0.000 claims 1
- 125000004069 aziridinyl group Chemical group 0.000 claims 1
- 210000000459 calcaneus Anatomy 0.000 claims 1
- 235000009120 camo Nutrition 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 235000005607 chanvre indien Nutrition 0.000 claims 1
- 125000000068 chlorophenyl group Chemical group 0.000 claims 1
- 201000007717 corneal ulcer Diseases 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- KTHXBEHDVMTNOH-UHFFFAOYSA-N cyclobutanol Chemical compound OC1CCC1 KTHXBEHDVMTNOH-UHFFFAOYSA-N 0.000 claims 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- QCRFMSUKWRQZEM-UHFFFAOYSA-N cycloheptanol Chemical compound OC1CCCCCC1 QCRFMSUKWRQZEM-UHFFFAOYSA-N 0.000 claims 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 230000001419 dependent Effects 0.000 claims 1
- 231100000080 dermatitis contact Toxicity 0.000 claims 1
- 235000019821 dicalcium diphosphate Nutrition 0.000 claims 1
- 125000006001 difluoroethyl group Chemical group 0.000 claims 1
- 201000008370 discitis Diseases 0.000 claims 1
- 201000009910 diseases by infectious agent Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drugs Drugs 0.000 claims 1
- CKSJXOVLXUMMFF-UHFFFAOYSA-N exalamide Chemical compound CCCCCCOC1=CC=CC=C1C(N)=O CKSJXOVLXUMMFF-UHFFFAOYSA-N 0.000 claims 1
- 230000000893 fibroproliferative Effects 0.000 claims 1
- 230000002538 fungal Effects 0.000 claims 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N furane Chemical group C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims 1
- 201000011066 hemangioma Diseases 0.000 claims 1
- 239000011487 hemp Substances 0.000 claims 1
- 235000012765 hemp Nutrition 0.000 claims 1
- 125000005842 heteroatoms Chemical group 0.000 claims 1
- 201000008298 histiocytosis Diseases 0.000 claims 1
- 201000003943 hypersensitivity reaction type III disease Diseases 0.000 claims 1
- 201000006362 hypersensitivity vasculitis Diseases 0.000 claims 1
- 200000000018 inflammatory disease Diseases 0.000 claims 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 1
- 150000002537 isoquinolines Chemical class 0.000 claims 1
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims 1
- 239000004571 lime Substances 0.000 claims 1
- 230000003211 malignant Effects 0.000 claims 1
- 235000012766 marijuana Nutrition 0.000 claims 1
- 230000001394 metastastic Effects 0.000 claims 1
- 230000036473 myasthenia Effects 0.000 claims 1
- 201000009629 myofascial pain syndrome Diseases 0.000 claims 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 201000008383 nephritis Diseases 0.000 claims 1
- 210000002569 neurons Anatomy 0.000 claims 1
- 230000002981 neuropathic Effects 0.000 claims 1
- 125000001715 oxadiazolyl group Chemical group 0.000 claims 1
- 244000045947 parasites Species 0.000 claims 1
- 201000006651 patellofemoral pain syndrome Diseases 0.000 claims 1
- 239000000546 pharmaceutic aid Substances 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 230000002028 premature Effects 0.000 claims 1
- 201000002728 primary biliary cirrhosis Diseases 0.000 claims 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propanol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N pyrazole Chemical group C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 150000003248 quinolines Chemical class 0.000 claims 1
- 201000003068 rheumatic fever Diseases 0.000 claims 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 238000000926 separation method Methods 0.000 claims 1
- 201000001223 septic arthritis Diseases 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 210000000456 talus bone Anatomy 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 1
- 125000000147 tetrahydroquinolinyl group Chemical class N1(CCCC2=CC=CC=C12)* 0.000 claims 1
- 230000001052 transient Effects 0.000 claims 1
- 125000004205 trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims 1
- 125000000725 trifluoropropyl group Chemical group [H]C([H])(*)C([H])([H])C(F)(F)F 0.000 claims 1
- 208000002514 type 1 Stickler syndrome Diseases 0.000 claims 1
- 201000006704 ulcerative colitis Diseases 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023200631A JP2024026193A (ja) | 2018-01-25 | 2023-11-28 | Ｒｈｏ関連プロテインキナーゼのモジュレーター |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1801226.0 | 2018-01-25 | ||
| GBGB1801226.0A GB201801226D0 (en) | 2018-01-25 | 2018-01-25 | Modulators of Rho-associated protein kinase |
| PCT/GB2019/050215 WO2019145729A1 (en) | 2018-01-25 | 2019-01-25 | Heterocyclylamino-substituted triazoles as modulators of rho-associated protein kinase |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023200631A Division JP2024026193A (ja) | 2018-01-25 | 2023-11-28 | Ｒｈｏ関連プロテインキナーゼのモジュレーター |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021512158A JP2021512158A (ja) | 2021-05-13 |
| JPWO2019145729A5 true JPWO2019145729A5 (es) | 2022-01-31 |
Family
ID=61558335
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020561950A Pending JP2021512158A (ja) | 2018-01-25 | 2019-01-25 | Ｒｈｏ関連プロテインキナーゼのモジュレーター |
| JP2023200631A Pending JP2024026193A (ja) | 2018-01-25 | 2023-11-28 | Ｒｈｏ関連プロテインキナーゼのモジュレーター |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023200631A Pending JP2024026193A (ja) | 2018-01-25 | 2023-11-28 | Ｒｈｏ関連プロテインキナーゼのモジュレーター |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US11497751B2 (es) |
| EP (2) | EP3743420B1 (es) |
| JP (2) | JP2021512158A (es) |
| KR (1) | KR20200113216A (es) |
| CN (1) | CN111655681B (es) |
| AU (1) | AU2019213214B2 (es) |
| BR (1) | BR112020013759A2 (es) |
| CA (1) | CA3088330A1 (es) |
| CY (1) | CY1125017T1 (es) |
| DK (1) | DK3743420T3 (es) |
| EA (1) | EA202091711A1 (es) |
| ES (1) | ES2907833T3 (es) |
| GB (1) | GB201801226D0 (es) |
| HR (1) | HRP20220269T8 (es) |
| HU (1) | HUE058940T2 (es) |
| IL (1) | IL275988B2 (es) |
| LT (1) | LT3743420T (es) |
| MX (1) | MX2020007898A (es) |
| PH (1) | PH12020550986A1 (es) |
| PL (1) | PL3743420T3 (es) |
| PT (1) | PT3743420T (es) |
| SG (1) | SG11202006087UA (es) |
| SI (1) | SI3743420T1 (es) |
| WO (1) | WO2019145729A1 (es) |
| ZA (1) | ZA202003983B (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201801226D0 (en) | 2018-01-25 | 2018-03-14 | Redx Pharma Plc | Modulators of Rho-associated protein kinase |
| CN111718310B (zh) * | 2019-08-19 | 2021-06-11 | 中国药科大学 | 苯基取代的五元杂环类化合物及其制备方法、用途和药物组合物 |
| CN110845410B (zh) * | 2019-10-29 | 2021-02-26 | 暨明医药科技（苏州）有限公司 | 一种一锅法制备6,7-二甲氧基-3,4-二氢异喹啉盐酸盐的方法 |
| IL310209A (en) * | 2021-07-26 | 2024-03-01 | Harvard College | ROCK2 inhibitors and their uses |
| CN113999211B (zh) * | 2021-11-23 | 2022-11-29 | 郑州大学 | 一类特异性抗前列腺癌活性的含1,2,3-三氮唑的吲唑骨架衍生物 |
| GB202200735D0 (en) * | 2022-01-20 | 2022-03-09 | Redx Pharma Plc | Compounds |
| WO2023182856A1 (ko) * | 2022-03-24 | 2023-09-28 | 서울대학교산학협력단 | 로-키나제 억제제를 포함하는 켈로이드 등 피부 섬유화 질환의 예방 또는 치료용 약학적 조성물 및 그의 용도 |
| CN116891460A (zh) * | 2023-07-12 | 2023-10-17 | 浙江大学 | 一种吲唑类衍生物或其药用盐及应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9207396D0 (en) | 1992-04-03 | 1992-05-13 | Merck Sharp & Dohme | Therapeutic agents |
| DE60120193T2 (de) * | 2000-09-15 | 2007-03-29 | Vertex Pharmaceuticals Inc., Cambridge | Pyrazolverbindungen als protein-kinasehemmer |
| CL2003002353A1 (es) * | 2002-11-15 | 2005-02-04 | Vertex Pharma | Compuestos derivados de diaminotriazoles, inhibidores d ela proteina quinasa; composicion farmaceutica; procedimiento de preparacion; y su uso del compuesto en el tratamiento de enfermedades de desordenes alergicos, proliferacion, autoinmunes, condic |
| AU2003293376A1 (en) * | 2002-12-10 | 2004-06-30 | Imclone Systems Incorporated | Anti-angiogenic compounds and their use in cancer treatment |
| EP1730124A4 (en) * | 2004-03-26 | 2009-04-01 | Amphora Discovery Corp | Certain compounds based on triazole, compositions and applications thereof |
| WO2006135383A2 (en) * | 2004-08-04 | 2006-12-21 | Myriad Genetics, Inc. | Indazoles |
| AU2007267859B2 (en) | 2006-05-25 | 2012-04-12 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate Hsp90 activity |
| DE102007022565A1 (de) * | 2007-05-14 | 2008-11-20 | Merck Patent Gmbh | Heterocyclische Indazolderivate |
| CA2727928A1 (en) * | 2008-06-18 | 2009-12-23 | Merck Sharp & Dohme Corp. | Inhibitors of janus kinases |
| AU2011232372B2 (en) * | 2010-03-24 | 2016-06-30 | Amitech Therapeutic Solutions, Inc. | Heterocyclic compounds useful for kinase inhibition |
| US9061966B2 (en) | 2010-10-08 | 2015-06-23 | Oryzon Genomics S.A. | Cyclopropylamine inhibitors of oxidases |
| SI2655357T1 (sl) | 2010-12-20 | 2016-10-28 | Merck Serono S.A. | Derivati indazolil triazola kot zaviralci IRAK |
| EP2824099A4 (en) * | 2012-03-09 | 2015-11-11 | Carna Biosciences Inc | NOVEL TRIAZINE DERIVATIVE |
| EP3262041A4 (en) * | 2015-02-27 | 2018-08-01 | Lycera Corporation | Indazolyl thiadiazolamines and related compounds for inhibition of rho-associated protein kinase and the treatment of disease |
| CO2018006164A2 (es) | 2015-12-16 | 2018-09-20 | Loxo Oncology Inc | Compuestos útiles como inhibidores de cinasa |
| EP3421464B1 (en) * | 2017-06-30 | 2021-11-24 | Beijing Tide Pharmaceutical Co., Ltd. | Rho-associated protein kinase inhibitor, pharmaceutical composition comprising the same, as well as preparation method and use thereof |
| GB201801226D0 (en) | 2018-01-25 | 2018-03-14 | Redx Pharma Plc | Modulators of Rho-associated protein kinase |
-
2018
- 2018-01-25 GB GBGB1801226.0A patent/GB201801226D0/en not_active Ceased
-
2019
- 2019-01-25 EP EP19702694.1A patent/EP3743420B1/en active Active
- 2019-01-25 KR KR1020207022578A patent/KR20200113216A/ko not_active Application Discontinuation
- 2019-01-25 CA CA3088330A patent/CA3088330A1/en active Pending
- 2019-01-25 WO PCT/GB2019/050215 patent/WO2019145729A1/en active Application Filing
- 2019-01-25 ES ES19702694T patent/ES2907833T3/es active Active
- 2019-01-25 LT LTEPPCT/GB2019/050215T patent/LT3743420T/lt unknown
- 2019-01-25 HU HUE19702694A patent/HUE058940T2/hu unknown
- 2019-01-25 JP JP2020561950A patent/JP2021512158A/ja active Pending
- 2019-01-25 AU AU2019213214A patent/AU2019213214B2/en active Active
- 2019-01-25 MX MX2020007898A patent/MX2020007898A/es unknown
- 2019-01-25 BR BR112020013759-6A patent/BR112020013759A2/pt unknown
- 2019-01-25 DK DK19702694.1T patent/DK3743420T3/da active
- 2019-01-25 EP EP21214072.7A patent/EP4026834A1/en active Pending
- 2019-01-25 HR HRP20220269TT patent/HRP20220269T8/hr unknown
- 2019-01-25 SI SI201930178T patent/SI3743420T1/sl unknown
- 2019-01-25 CN CN201980010083.3A patent/CN111655681B/zh active Active
- 2019-01-25 PL PL19702694T patent/PL3743420T3/pl unknown
- 2019-01-25 EA EA202091711A patent/EA202091711A1/ru unknown
- 2019-01-25 SG SG11202006087UA patent/SG11202006087UA/en unknown
- 2019-01-25 US US16/964,904 patent/US11497751B2/en active Active
- 2019-01-25 PT PT197026941T patent/PT3743420T/pt unknown
-
2020
- 2020-06-25 PH PH12020550986A patent/PH12020550986A1/en unknown
- 2020-06-30 ZA ZA2020/03983A patent/ZA202003983B/en unknown
- 2020-07-12 IL IL275988A patent/IL275988B2/en unknown
-
2022
- 2022-02-16 CY CY20221100132T patent/CY1125017T1/el unknown
- 2022-08-26 US US17/896,626 patent/US11878020B2/en active Active
-
2023
- 2023-11-28 JP JP2023200631A patent/JP2024026193A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104903312B (zh) | Rho激酶抑制剂 | |
| CN104837832B (zh) | Gdf-8抑制剂 | |
| JP2021508686A5 (es) | ||
| JP2020172535A5 (es) | ||
| US11591342B2 (en) | Heterocyclic compound, application thereof and pharmaceutical composition comprising same | |
| JP2015503505A5 (es) | ||
| JP2023010738A (ja) | 抗癌活性及び抗増殖活性を呈する２－アミノピリミジン－６－オン及び類似体 | |
| JPWO2019145729A5 (es) | ||
| RU2016141647A (ru) | ИНГИБИТОРЫ TrkA КИНАЗЫ, ОСНОВАННЫЕ НА НИХ КОМПОЗИЦИИ И СПОСОБЫ | |
| JP2021507900A5 (es) | ||
| HRP20220269T1 (hr) | Heterociklilamino-supstituirani triazoli kao modulatori rho-povezane protein kinaze | |
| CA2496676A1 (en) | 3,4-di-substituted cyclobutene-1,2-diones as cxc-chemokine receptor ligands | |
| JP2009539878A5 (es) | ||
| US20170239226A1 (en) | N-Substituted-5-Substituted Phthalamic Acids as Sortilin Inhibitors | |
| AU2007284562A1 (en) | Using PI3K and MEK modulators in treatments of cancer | |
| CN106536507A (zh) | 作为TGF‑β抑制剂的2,3‑二取代的吡啶化合物及其使用方法 | |
| JP2003519130A5 (es) | ||
| CN103420977A (zh) | 具有抗肿瘤活性的乙炔衍生物 | |
| CN104024252A (zh) | 用于治疗肺动脉高压的双环杂环衍生物 | |
| CN104837828A (zh) | 作为pde4-抑制剂的苯基乙基吡啶衍生物 | |
| JP2022518853A (ja) | 免疫調節剤 | |
| EP2817292A1 (en) | Sulfonamide compounds and uses as tnap inhibitors | |
| CN101537001A (zh) | 作为jak-stat3信号通路抑制剂的化合物的应用 | |
| EP2231282A1 (en) | Protein kinase inhibitors and use thereof | |
| JP2022500466A (ja) | 抗ウイルス剤としての官能化複素環 |